LATEST from ForumIAS
- 17 May | Exam Day Strategy for UPSC Prelims 2026 Click Here →
- 17 May | ABC of Indian Sociology Series | 'H' = HAROLD COULD | Sociology Optional Simplified. Click Here to watch Smriti Mam explain the concept in simple terms →
- 15 May | If You Are Giving Prelims 2026, Watch This Before Entering the Exam Hall Click Here to listen to Ayush Sir's advice →
- Two tuberculosis survivors from Indian and South Africa have challenged Johnson and Johnson’s application to extend the patent over Bedaquiline, in order to keep it affordable for everyone.
- Bedaquiline is a drug used to treat multidrug-resistant tuberculosis (MDR-TB). MDR-TB is a condition where the TB bacteria has developed resistance to most antibiotic drugs.
- The J&J patent application is being challenged on the grounds that the new salt form of Bedaquiline, does not merit patenting under India’s Patents Act, 1970. This is because it is a minor reformulation of the drug without any increase in therapeutic efficacy – often called as patent evergreening
- In India, the high price of Bedaquiline is a significant barrier for the government to make it available to all patients, thus exposing patients to less effective drugs with severe side effects.
